PepGen (NASDAQ:PEPG) Stock, Quote.Headers.trade-ideas

PepGen

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

Roku.Shutterstock

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADSK

BELFB

COIN

PEPG

PLUG

ROKU

SNDX

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday

Biotech

Large Cap

Technicals

Small Cap

General

CAPR

SRPT

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD).

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher


Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor’s stock surged more than

PepGen Inc

HBAN

Huntington Bancshares Says Momentum From Core Businesses And Investments To Carry Through 2025 And Beyond, With A 'Robust' Growth Outlook And ;Expanded Profitability'

Needham analyst John Todaro reiterates Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $22 price target.

Reiteration

BTDR

Needham Reiterates Buy on Bitdeer Technologies, Maintains $22 Price Target

Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. The company reported quarterly sales of $1.954 billion which beat the analyst consensus estimate of $1.888 billion by 3.50 percent. This is a 13.54 percent increase over sales of $1.721 billion the same period last year.

Earnings

Earnings Beats

Huntington Bancshares Q4 Sales $1.954B Beat $1.888B Estimate

This product addresses the critical need for non-Chinese, NDAA-compliant components in the U.S. drone industry. Unusual machines now has two drone components placed on the Blue UAS Framework.

UMAC

Unusual Machines Reveals The Release Of The Rotor Riot Brave 55A ESC And Its Addition To The Blue UAS Framework

WIIM

State Street shares are trading lower despite better-than-expected Q4 results.

Wolfe Research analyst Devin Brisco downgrades Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Outperform to Peer Perform.

Downgrades

SPOT

Wolfe Research Downgrades Spotify Technology to Peer Perform

INVH

Invitation Homes shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and price target of $38.

Novo Nordisk Reveals Headline Results From STEP UP, A Phase 3b Trial In Global STEP Program; Company Says STEP UP Is A 72-week Efficacy And Safety Trial Investigating Subcutaneous Semaglutide 7.2MG Compared To Semaglutide 2.4MG And Placebo, All Administered Once Weekly

CWAN

Clearwater Analytics shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $30 to $34.

QRVO

Qorvo shares are trading higher following a WSJ report indicating activist investor Starboard Value has acquired a 7.7% stake in the company.

The change in exchange ratio for the ADSs will have the same effect as a 1-for-40 reverse stock split of the ADSs, reducing the number of outstanding ADSs from 142,340,133 to 3,558,503 ADSs.&nbsp;

BLRX

BioLineRx Reports Change To Ratio Of American Depositary Shares To Ordinary Shares; Change In Exchange Ratio To Have Same Effect As 1-For-40 Reverse Stock Split

Evercore ISI Group analyst Mark Mahaney downgrades Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from Outperform to In-Line and announces $23 price target.

WRBY

Evercore ISI Group Downgrades Warby Parker to In-Line, Announces $23 Price Target

JP Morgan analyst Rajat Gupta maintains Asbury Automotive Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABG#NYSE">ABG</a>) with a Neutral and lowers the price target from $260 to $255.

JP Morgan Maintains Neutral on Asbury Automotive Gr, Lowers Price Target to $255

AUTL

Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes

Needham analyst Ryan MacDonald reiterates Udemy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) with a Buy and maintains $11 price target.

UDMY

Needham Reiterates Buy on Udemy, Maintains $11 Price Target

CLSK

IREN

MARA

MSTB

MSTR

RIOT

WULF

Shares of crypto stocks and Bitcoin miners are trading higher amid a rise in Bitcoin.

Needham analyst James Ricchiuti maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Buy and lowers the price target from $245 to $182.

Needham Maintains Buy on Impinj, Lowers Price Target to $182

JP Morgan analyst Matthew Boss maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Underweight and lowers the price target from $176 to $166.

JP Morgan Maintains Underweight on Vail Resorts, Lowers Price Target to $166

FRSX

Foresight Autonomous Holdings Says Its Unit Eye-net Mobile Has Successfully Passed Rigorous Field Tests Conducted By UTAC, A French Organization Specializing In Vehicle Testing, Certification, And Safety Solutions

JP Morgan analyst Matthew Boss maintains Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Overweight and raises the price target from $50 to $58.

JP Morgan Maintains Overweight on Viking Holdings, Raises Price Target to $58

BofA lowered the firm's price target on PepGen (PEPG) to $6 from $10 and keeps a Neutral rating on the shares after the company announced several c...

PepGen price target lowered to $6 from $10 at BofA

Dyne, Avidity initiated at outperform by RBC on DM1 drugs

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2024 Update

PepGen (PEPG) announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration FDA regarding its Investigation...

FDA issues clinical hold notice to PepGen on IND app for CONNECT2-EDO51 trial

PepGen stock craters 35% on FDA clinical hold

BofA downgraded PepGen (PEPG) to Underperform from Neutral with a $3 price target Published first on TheFly – the ultimate source for real-time, ma...

PepGen downgraded to Underperform from Neutral at BofA

BofA downgraded PepGen (PEPG) to Underperform from Neutral with a price target of $3, down from $6, after the FDA placed a clinical hold on the com...

BofA downgrades PepGen to Underperform after clinical hold

PepGen stock down 22% on FDA clinical hold (update)

PepGen (PEPG) announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy, wh...

PepGen clinical hold likely to be resolved quickly, says Leerink

Healthcare Analyst Tsai, along with Dr. Conrad Nievera, discuss rare muscle diseases, (relevant companies SRPT DYN RNA PEPG CAPR) on an Analyst/Ind...

Jefferies healthcare analyst holds an analyst/industry conference call

AAPL

ACHC

ADBE

ADPT

AMZN

ARWR

AVGO

BBIO

BMRN

CBRE

CPRX

DASH

DDOG

DLTR

EWTX

FERG

FLUT

HRMY

INBX

ISRG

MSCLF

MSFT

NAMS

NFLX

NVDA

ORIC

PHVS

RGNX

RHHBY

ROIV

RPRX

SLDB

TEAM

TMUS

TRDA

TRVI

VKTX

VRTX

WDAY

Press Releases

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen to Participate in Upcoming Investor Conferences

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Comments

PepGen

PepGen (PEPG) Forecast

PepGen (NASDAQ:PEPG) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga